Advertisement

An Evaluation of Applicability of Salivary Uric Acid Measurement in Preeclampsia and Normal Pregnancy and Its Correlation with Serum Uric Acid

  • Urmila Singh
  • Vandana SolankiEmail author
  • Seema Mehrotra
  • Ruchita Sharma
Original Article
  • 17 Downloads

Abstract

Purpose

Hypertensive disorders complicate 5–10% of all pregnancies and contribute greatly to maternal morbidity and mortality. There are various biomarkers for detection of preeclampsia. Several studies have reported that positive correlation exists between serum uric acid (UA) levels and adverse maternal and fetal outcome. Significant advances have been made toward validation of salivary biomarkers. We conducted this study to determine levels of salivary UA and its correlation with serum UA normal pregnancy and preeclampsia.

Methods

Present cross-sectional study was conducted in tertiary care teaching hospital in North India. One hundred and fifty participants were divided into control group (50 healthy non-pregnant females), study group I (50 normotensive pregnant females), study group II (50 pregnant females with preeclampsia), and both salivary and serum UA was estimated at the same time.

Results

Saliva UA of study group II (4.86 ± 2.37 mg/dl) was significantly higher (p < 0.001) than that of control group (2.09 ± 1.33 mg/dl) and study group I (3.32 ± 1.77 mg/dl). Serum UA of study group II (6.63 + 2.78 mg/dl) was significantly higher (p < 0.001) than that of control group (2.94 + 1.94 mg/dl) and also study group I (5.18 + 2.31 mg/dl) (p = 0.0006).

Conclusion

UA is present in the saliva of women with preeclampsia and has linear correlation with serum UA. Therefore, salivary UA can be used in place of invasive serum UA to monitor women with preeclampsia. Saliva collection is easy, noninvasive and cost-effective. Salivary UA testing may be useful for monitoring preeclampsia at home-based and hospital setting.

Keywords

Saliva Uric acid Preeclampsia 

Abbreviation

UA

Uric acid

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed Consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Duley L. Maternal mortality associated with hypertensive disorder of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99(7):547–53.CrossRefGoogle Scholar
  2. 2.
    Many A, Hubel CA, Roberts JM. Hyperuricaemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174(1):288–91.CrossRefGoogle Scholar
  3. 3.
    Powers RW, Bodnar LM, Ness RB, et al. Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am J Obstet Gynecol. 2006;194(1):160.  https://doi.org/10.1016/j.ajog.2005.06.066.CrossRefGoogle Scholar
  4. 4.
    Lippi G, Montagnana M, Franchini M, et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008;392(1–2):1–7.  https://doi.org/10.1016/j.cca.2008.02.024.CrossRefGoogle Scholar
  5. 5.
    Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.CrossRefGoogle Scholar
  6. 6.
    Soukup M, Biesiada I, Henderson A, et al. Salivary uric acid as a non invasive biomarker of metabolic syndrome. Diabetol Metab Syndr. 2012;4(1):14.  https://doi.org/10.1186/1758-5996-4-14.CrossRefGoogle Scholar
  7. 7.
    Sorensen LB. Role of the intestinal tract in the elimination of Uric acid. Arthritis And Rheum. 1965;8(5):694–706.CrossRefGoogle Scholar
  8. 8.
    Lam C, Lim K-H, Kang D-H, et al. Uric acid and preeclampsia. Semin Nephrol. 2005;25(1):56–60.  https://doi.org/10.1016/j.semnephrol.2004.09.009.CrossRefGoogle Scholar
  9. 9.
    Liedholm H, Montan S, Aberg A. Risk grouping of 113 patients with hypertensive disorders during pregnancy, with respect to serum urate, proteinuria and time of onset of hypertension. Acta Obstet Gynecol Scand Suppl. 1984;62(Suppl 118):43–8.CrossRefGoogle Scholar
  10. 10.
    Redman CW, Beilin LJ, Bonnar J, et al. Plasma-urate measurements in predicting fetal death in hypertensive pregnancy. Lancet. 1976;26:1370–3.CrossRefGoogle Scholar
  11. 11.
    Johnson RJ, Kanbay M, Kang D-H, et al. Uric acid: a clinically useful marker to distinguish preeclampsia from gestational hypertension. Hypertension. 2011;58(4):548–9.  https://doi.org/10.1161/hypertensionaha.111.178921.CrossRefGoogle Scholar
  12. 12.
    Akahori Y, Masuyama H, Hiramatsu Y. Correlation of maternal serum uric acid concentration with small for date gestational fetus in normotensive pregnant women. Gynecol Obstet Investig. 2012;73:162–7.  https://doi.org/10.1159/000332391.CrossRefGoogle Scholar
  13. 13.
    Chappell LC, Seed PT, Briley A, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynaecol. 2002;186:127–36.CrossRefGoogle Scholar
  14. 14.
    Cunningham FG (2014). Chapter 40: hypertensive disorders. In: Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, Casey BM, Sheffield JS, editors. Williams obstetrics, 24th ed. New York: McGraw-Hill Education. ISBN 9780071798938. OCLC 871619675.Google Scholar
  15. 15.
    Soukup M, Biesiada I, Henderson A, et al. Salivary uric acid as a noninvasive biomarker of metabolic syndrome. Diabetol Metab Syndr. 2012;4:14.  https://doi.org/10.1186/1758-5996-4-14.CrossRefGoogle Scholar
  16. 16.
    Hadi BA, Al-jubouri RH. Salivary and plasma analysis of oxidative stress biomarkers in end stage renal failure patients. J Bagh Coll Dent. 2011;23(2):46–50.Google Scholar
  17. 17.
    Blicharz TM, Rissin DM, Bowden M, et al. Use of colorimetric test strips for monitoring the effect of hemodialysis on salivary nitrite and uric acid in patients with end-stage renal disease: a proof of principle. Clin Chem. 2008;54(9):1473–80.  https://doi.org/10.1373/clinchem.2008.105320.CrossRefGoogle Scholar
  18. 18.
    Hawkins TL-A, Roberts JM, Mangos GJ, et al. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. BJOG. 2012;119(4):484–92.  https://doi.org/10.1111/j.1471-0528.2011.03232.x.CrossRefGoogle Scholar
  19. 19.
    Sangeeta N, Shaini L, Basar G, et al. Serum uric acid and homocysteine as predictors of pre-eclampsia. J Diabetes Metab. 2013;4:259.  https://doi.org/10.4172/2155-6156.1000259.Google Scholar
  20. 20.
    Tejal P, Astha D. Relationship of serum uric acid level to maternal and perinatal outcome in patients with hypertensive disorders of pregnancy. Gujarat Med J. 2014;69(2):45–7.Google Scholar
  21. 21.
    Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29(Suppl A):S67–72.  https://doi.org/10.1016/j.placenta.2007.11.001.CrossRefGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyKing George’s Medical UniversityLucknowIndia

Personalised recommendations